{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:35:30Z","timestamp":1794540930741,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K19756"],"award-info":[{"award-number":["24K19756"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K09731"],"award-info":[{"award-number":["22K09731"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10147-025-02797-z","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:48:23Z","timestamp":1749012503000},"page":"1572-1581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of medications on the efficacy of immune checkpoint inhibitors in patients with recurrent or metastatic head and neck cancer"],"prefix":"10.1007","volume":"30","author":[{"given":"Kiyoshi","family":"Minohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Matoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michi","family":"Sawabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3794-2790","authenticated-orcid":false,"given":"Daisuke","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Oguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Murashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tsuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Shingaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sekai","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomota","family":"Kamida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funa","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"19","key":"2797_CR1","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"issue":"10212","key":"2797_CR2","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/s0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915\u20131928. https:\/\/doi.org\/10.1016\/s0140-6736(19)32591-7","journal-title":"Lancet"},{"issue":"5","key":"2797_CR3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail DJ, Pili\u00e9 PG, Rashid NU et al (2021) High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 32(5):661\u2013672. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.006","journal-title":"Ann Oncol"},{"issue":"6371","key":"2797_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236","journal-title":"Science"},{"issue":"6264","key":"2797_CR5","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M V\u00e9tizou","year":"2015","unstructured":"V\u00e9tizou M, Pitt JM, Daill\u00e8re R et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350(6264):1079\u20131084. https:\/\/doi.org\/10.1126\/science.aad1329","journal-title":"Science"},{"issue":"4","key":"2797_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","volume":"31","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Cardona A, Nagarkar DR et al (2020) Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol 31(4):525\u2013531. https:\/\/doi.org\/10.1016\/j.annonc.2020.01.006","journal-title":"Ann Oncol"},{"key":"2797_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.716317","volume":"12","author":"Q Giordan","year":"2021","unstructured":"Giordan Q, Salleron J, Vallance C et al (2021) Impact of antibiotics and proton pump inhibitors on efficacy and tolerance of anti-PD-1 immune checkpoint inhibitors. Front Immunol 12:716317. https:\/\/doi.org\/10.3389\/fimmu.2021.716317","journal-title":"Front Immunol"},{"issue":"5","key":"2797_CR8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","volume":"65","author":"F Imhann","year":"2016","unstructured":"Imhann F, Bonder MJ, Vich Vila A et al (2016) Proton pump inhibitors affect the gut microbiome. Gut 65(5):740\u2013748. https:\/\/doi.org\/10.1136\/gutjnl-2015-310376","journal-title":"Gut"},{"key":"2797_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.oraloncology.2019.01.019","volume":"90","author":"A Gupta","year":"2019","unstructured":"Gupta A, Stokes W, Eguchi M et al (2019) Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer. Oral Oncol 90:54\u201366. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.01.019","journal-title":"Oral Oncol"},{"key":"2797_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005940","author":"V Kansal","year":"2023","unstructured":"Kansal V, Burnham AJ, Kinney BLC et al (2023) Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-005940","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2797_CR11","doi-asserted-by":"publisher","first-page":"1957605","DOI":"10.1080\/2162402x.2021.1957605","volume":"10","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Chen H, Chen S et al (2021) The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Oncoimmunology 10(1):1957605. https:\/\/doi.org\/10.1080\/2162402x.2021.1957605","journal-title":"Oncoimmunology"},{"issue":"2","key":"2797_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"8","key":"2797_CR13","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00384-006-0259-6","volume":"22","author":"DC McMillan","year":"2007","unstructured":"McMillan DC, Crozier JE, Canna K et al (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22(8):881\u2013886. https:\/\/doi.org\/10.1007\/s00384-006-0259-6","journal-title":"Int J Colorectal Dis"},{"key":"2797_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejca.2023.02.011","volume":"184","author":"A Wada","year":"2023","unstructured":"Wada A, Enokida T, Okano S et al (2023) Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 184:30\u201338. https:\/\/doi.org\/10.1016\/j.ejca.2023.02.011","journal-title":"Eur J Cancer"},{"issue":"17","key":"2797_CR15","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1200\/jco.22.00074","volume":"41","author":"L Eng","year":"2023","unstructured":"Eng L, Sutradhar R, Niu Y et al (2023) Impact of antibiotic exposure before immune checkpoint inhibitor treatment on overall survival in older adults with cancer: a population-based study. J Clin Oncol 41(17):3122\u20133134. https:\/\/doi.org\/10.1200\/jco.22.00074","journal-title":"J Clin Oncol"},{"issue":"4","key":"2797_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamaoncol.2017.5236","volume":"4","author":"G Ritchie","year":"2018","unstructured":"Ritchie G, Gasper H, Man J et al (2018) Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis. JAMA Oncol 4(4):522\u2013528. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5236","journal-title":"JAMA Oncol"},{"key":"2797_CR17","doi-asserted-by":"publisher","first-page":"1114499","DOI":"10.3389\/fimmu.2023.1114499","volume":"14","author":"A Singh","year":"2023","unstructured":"Singh A, Alexander SG, Martin S (2023) Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy. Front Immunol 14:1114499. https:\/\/doi.org\/10.3389\/fimmu.2023.1114499","journal-title":"Front Immunol"},{"issue":"20","key":"2797_CR18","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1158\/1078-0432.Ccr-21-1129","volume":"28","author":"D Davar","year":"2022","unstructured":"Davar D, Zarour HM (2022) Facts and hopes for gut microbiota interventions in cancer immunotherapy. Clin Cancer Res 28(20):4370\u20134384. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-1129","journal-title":"Clin Cancer Res"},{"issue":"6264","key":"2797_CR19","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A, Corrales L, Hubert N et al (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350(6264):1084\u20131089. https:\/\/doi.org\/10.1126\/science.aac4255","journal-title":"Science"},{"issue":"5","key":"2797_CR20","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41591-019-0439-x","volume":"25","author":"J Suez","year":"2019","unstructured":"Suez J, Zmora N, Segal E et al (2019) The pros, cons, and many unknowns of probiotics. Nat Med 25(5):716\u2013729. https:\/\/doi.org\/10.1038\/s41591-019-0439-x","journal-title":"Nat Med"},{"issue":"17","key":"2797_CR21","doi-asserted-by":"publisher","first-page":"5221","DOI":"10.1158\/1078-0432.Ccr-18-3944","volume":"25","author":"RL Ferris","year":"2019","unstructured":"Ferris RL, Licitra L, Fayette J et al (2019) Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use. Clin Cancer Res 25(17):5221\u20135230. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-3944","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2797_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/s1470-2045(20)30755-5","volume":"22","author":"J Guigay","year":"2021","unstructured":"Guigay J, Aup\u00e9rin A, Fayette J et al (2021) Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014\u201301 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 22(4):463\u2013475. https:\/\/doi.org\/10.1016\/s1470-2045(20)30755-5","journal-title":"Lancet Oncol"},{"issue":"24","key":"2797_CR23","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.21037\/atm-20-7498","volume":"8","author":"C Li","year":"2020","unstructured":"Li C, Xia Z, Li A et al (2020) The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ann Transl Med 8(24):1655. https:\/\/doi.org\/10.21037\/atm-20-7498","journal-title":"Ann Transl Med"},{"issue":"2","key":"2797_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1001\/jamaoto.2017.2561","volume":"144","author":"CA Riley","year":"2018","unstructured":"Riley CA, Wu EL, Hsieh MC et al (2018) Association of gastroesophageal reflux with malignancy of the upper aerodigestive tract in elderly patients. JAMA Otolaryngol Head Neck Surg 144(2):140\u2013148. https:\/\/doi.org\/10.1001\/jamaoto.2017.2561","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"12","key":"2797_CR25","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1158\/1940-6207.Capr-14-0002","volume":"7","author":"S Papagerakis","year":"2014","unstructured":"Papagerakis S, Bellile E, Peterson LA et al (2014) Proton pump inhibitors and histamine 2 blockers are associated with improved overall survival in patients with head and neck squamous carcinoma. Cancer Prev Res (Phila) 7(12):1258\u20131269. https:\/\/doi.org\/10.1158\/1940-6207.Capr-14-0002","journal-title":"Cancer Prev Res (Phila)"},{"key":"2797_CR26","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.161940","author":"W Mao","year":"2022","unstructured":"Mao W, Cai Y, Chen D et al (2022) Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non-small cell lung cancer. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.161940","journal-title":"JCI Insight"},{"issue":"6","key":"2797_CR27","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/cam4.4539","volume":"11","author":"D Kawakita","year":"2022","unstructured":"Kawakita D, Oze I, Iwasaki S et al (2022) Trends in the incidence of head and neck cancer by subsite between 1993 and 2015 in Japan. Cancer Med 11(6):1553\u20131560. https:\/\/doi.org\/10.1002\/cam4.4539","journal-title":"Cancer Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02797-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02797-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02797-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T07:37:14Z","timestamp":1753429034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02797-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2797"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02797-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"23 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of Nagoya City University Graduate School of Medical Sciences (approval no. 60-21-0001) and was conducted in accordance with the Declaration of Helsinki and current ethical guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"As this was a retrospective, non-interventional study, patients could reject participation by opting for an announcement on the Nagoya City University Hospital website, and the requirement for written informed consent was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}